Analysts Set Expectations for GYRE Q3 Earnings

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Analysts at Noble Financial issued their Q3 2026 earnings estimates for shares of Gyre Therapeutics in a research report issued on Monday, August 10th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings per share of ($0.10) for the quarter. The consensus estimate for Gyre Therapeutics’ current full-year earnings is ($0.30) per share. Noble Financial also issued estimates for Gyre Therapeutics’ Q4 2026 earnings at ($0.11) EPS.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $29.11 million during the quarter, compared to analysts’ expectations of $26.49 million. Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%.

A number of other analysts have also recently commented on the stock. Wall Street Zen cut shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Gyre Therapeutics in a report on Friday, August 7th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Gyre Therapeutics has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Up 2.5%

GYRE opened at $6.98 on Wednesday. The firm’s fifty day simple moving average is $6.35 and its two-hundred day simple moving average is $7.00. Gyre Therapeutics has a 52-week low of $5.44 and a 52-week high of $9.42. The company has a market cap of $778.34 million, a price-to-earnings ratio of -33.24 and a beta of 1.92.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, COO Weiguo Ye sold 12,820 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $6.15, for a total value of $78,843.00. Following the completion of the sale, the chief operating officer owned 700,000 shares in the company, valued at approximately $4,305,000. This represents a 1.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE increased its holdings in shares of Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after buying an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after acquiring an additional 3,244 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Gyre Therapeutics in the 4th quarter worth $77,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Gyre Therapeutics by 132.4% during the 4th quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after acquiring an additional 7,361 shares during the period. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.